AbbVie's Rinvoq rollout on track despite JAK safety concerns, but uncertainty remains: analyst

Just a few months ago, AbbVie's Rinvoq was riding high—and racing toward two new indications to boot. But after in-class rival Xeljanz put up some unflattering heart safety data, the FDA tapped the brakes on both those potential approvals, delaying decisions until later this year.

Not to worry, one analyst says. After surveying nearly two dozen rheumatologists, Evercore ISI's Josh Schimmer figures Rinvoq's still headed toward blockbusterland.